Efficacy and safety of ceritinib in patients (pts) with ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM) -results from ASCEND-2 and ASCEND-3

被引：0
|
作者：
Park, K. [1 ]
Tan, D. [2 ]
Ahn, M. -J. [3 ]
Yu, C. -J. [4 ]
Tsai, C. -M. [5 ]
Hida, T. [6 ]
Nishio, M. [7 ]
Branle, F. [8 ]
Emeremni, C. [9 ]
Mok, T. [10 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea
[2] Natl Canc Ctr, Med Oncol, Singapore, Singapore
[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[4] Natl Taiwan Univ, Dept Internal Med, Taipei 10764, Taiwan
[5] Taipei Vet Gen Hosp, Dept Chest Med, Taipei, Taiwan
[6] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi 464, Japan
[7] Japanese Fdn Canc Res, Dept Thorac Med Oncol, Tokyo, Japan
[8] Novartis Pharma AG, Oncol Clin Dev, Basel, Switzerland
[9] Novartis Pharma AG, Biometr & Data Management, E Hanover, NJ USA
[10] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
419O
引用
收藏
页码：126 / 127
页数：2
相关论文
共 50 条
  • [1] Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials
    Felip, E.
    Crino, L.
    Kim, D. -W.
    Spigel, D. R.
    Nishio, M.
    Mok, T.
    Scagliotti, G.
    Cesic, D.
    Sutradhar, S.
    Shaw, A. T.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S118 - S119
  • [2] Experience from the ASCEND-1 trial: Ceritinib in patients (Pts) with ALK-rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) and brain metastases
    Thomas, M.
    Schuler, M.
    Potzner, M.
    Szczudlo, T.
    Sutradhar, S.
    Yovine, A.
    Wolf, J.
    Oncology Research and Treatment, 2015, 38 : 270 - 270
  • [3] CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK plus ) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL
    Shaw, Alice
    Mehra, Ranee
    Tan, Daniel S. W.
    Felip, Enriqueta
    Chow, Laura Q. M.
    Camidge, D. Ross
    Vansteenkiste, Johan
    Sharma, Sunil
    De Pas, Tommaso
    Riely, Gregory J.
    Solomon, Benjamin J.
    Wolf, Juergen
    Thomas, Michael
    Schuler, Martin
    Liu, Geoffrey
    Santoro, Armando
    Geraldes, Margarida
    Sen, Paramita
    Boral, Anthony J.
    Yovine, Alejandro
    Kim, Dong-Wan
    NEURO-ONCOLOGY, 2014, 16
  • [4] Whole body and intracranial efficacy of ceritinib in ALK-inhibitor (ALKi)-naive patients (pts) with ALK-rearranged (ALK plus ) NSCLC and baseline (BL) brain metastases (BM): Results from ASCEND-1 and-3.
    Felip, Enriqueta
    Tan, Daniel Shao-Weng
    Kim, Dong-Wan
    Mehra, Ranee
    Orlov, Sergey
    Park, Keunchil
    Yu, Chong-Jen
    Mok, Tony
    Nishio, Makoto
    Scagliotti, Giorgio V.
    Spigel, David R.
    Sutradhar, Santosh
    Cesic, Dajana
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] WHOLE BODY AND INTRACRANIAL EFFICACY OF CERITINIB IN ALK-INHIBITOR (ALKi)-NAIVE PATIENTS WITH ALK-REARRANGED (ALK plus ) NSCLC AND BASELINE BRAIN METASTASES (BM): RESULTS FROM ASCEND-1 AND-3
    Mehra, Ranee
    Felip, Enriqueta
    Tan, Daniel Shao-Weng
    Kim, Dong-Wan
    Orlov, Sergey
    Park, Keunchil
    Yu, Chong-Jen
    Mok, Tony
    Nishio, Makoto
    Scagliotti, Giorgio V.
    Spigel, David R.
    Sutradhar, Santosh
    Cesic, Dajana
    Shaw, Alice Tsang
    NEURO-ONCOLOGY, 2016, 18 : 28 - 29
  • [6] Overall survival results of ceritinib in ALKi-naive patients with ALK-rearranged NSCLC (ASCEND-3)
    Felip, E.
    Nishio, M.
    Orlov, S.
    Park, K.
    Yu, C-J.
    Tsai, C-M.
    Cobo, M.
    McKeage, M.
    Su, W-C.
    Mok, T. S. K.
    Scagliotti, G. V.
    Spigel, D.
    Passos, V. Q.
    Chen, Z.
    Shaw, A. T.
    ANNALS OF ONCOLOGY, 2018, 29 : 745 - 745
  • [7] Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1
    Kim, D.
    Mehra, R.
    Tan, D. S. W.
    Felip, E.
    Chow, L. Q. M.
    Camidge, D. R.
    Vansteenkiste, J.
    Sharma, S.
    De Pas, T.
    Riely, G. J.
    Solomon, B. J.
    Wolf, J.
    Thomas, M.
    Schuler, M.
    Liu, G.
    Santoro, A.
    Geraldes, M.
    Boral, A. L.
    Yovine, A.
    Shaw, A. T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S33 - S34
  • [8] ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naive adult patients (pts) with ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC).
    Felip, Enriqueta
    Orlov, Sergey
    Park, Keunchil
    Yu, Chong-Jen
    Tsai, Chun-Ming
    Nishio, Makoto
    Dols, Manuel Cobo
    McKeage, Mark James
    Su, Wu-Chou
    Mok, Tony
    Scagliotti, Giorgio V.
    Spigel, David
    Branle, Fabrice
    Emeremni, Chetachi
    Quadrigli, Massimiliano
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] The phase II ASCEND-7 (CLDK378A2205) trial: Ceritinib in patients (pts) with ALK-rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) metastatic to the brain and/or leptomeninges
    Wolf, J.
    Schneider, C-P
    Potzner, M.
    Arratia, Cazorla P.
    Shen, J.
    Branle, F.
    von Pawel, J.
    Oncology Research and Treatment, 2015, 38 : 138 - 138
  • [10] Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK plus ) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial
    Kim, Dong-Wan
    Mehra, Ranee
    Tan, Daniel Shao-Weng
    Felip, Enriqueta
    Chow, Laura Quan Man
    Camidge, D. Ross
    Vansteenkiste, Johan F.
    Sharma, Sunil
    De Pas, Tommaso
    Riely, Gregory J.
    Solomon, Benjamin J.
    Wolf, Juergen
    Thomas, Michael
    Schuler, Martin H.
    Liu, Geoffrey
    Santoro, Armando
    Geraldes, Margarida
    Boral, Anthony
    Yovine, Alejandro Javier
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345